Zymeworks (ZYME) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
BenzingaNov 22 06:54 ET
Zymeworks Hold Rating: Balancing FDA Milestones With Market Valuation and Future Risks
TipRanksNov 22 06:25 ET · Ratings
Leerink Partners Maintains Zymeworks(ZYME.US) With Buy Rating, Raises Target Price to $26
Moomoo NewsNov 21 16:31 ET · Ratings
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
WSJNov 21 09:30 ET
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
MT NewswiresNov 21 09:13 ET
Express News | Zymeworks Inc : Leerink Partners Raises Target Price to $26 From $25
ReutersNov 21 08:55 ET

Comments

Meltyy

Nov 26 01:17

🚨 1 PDUFA this week!

See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...

6

Jaguar8

Jul 22 05:03

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Inc. (Nasdaq: ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW191, a novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). ZW191 targets FR⍺-expressing tumors, including ovarian, gynecological cancers, and non-small...

Jaguar8

Jun 17 06:42

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks (Nasdaq: ZYME) announced that the FDA has cleared its investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody designed to treat mesothelin (MSLN)-expressing cancers such as ovarian cancer, non-small cell lung cancer, and mesothelioma. ZW171 aims to i...

1